What are the causes of refractory hyperkalemia on arterial blood gas?

Refractory Hyperkalemia on Arterial Blood Gas

Refractory hyperkalemia on ABG most commonly results from pseudohyperkalemia caused by hemolysis during blood draw, prolonged tourniquet application with fist clenching, or in vitro potassium release from cells—verify with a venous sample drawn atraumatically before pursuing further workup. 1, 2

---

Immediate Verification: Rule Out Pseudohyperkalemia

Before attributing elevated potassium on ABG to true hyperkalemia, exclude laboratory artifact:

• Hemolysis during arterial puncture is the most common cause of falsely elevated potassium on ABG; inspect the sample for pink discoloration and request a repeat venous sample with atraumatic technique. 1, 3
• Prolonged tourniquet time with fist clenching during venous sampling causes local potassium release from muscle cells; this artifact is less common with arterial sampling but can occur if the radial artery is compressed excessively. 1, 3
• In vitro potassium release from leukocytes or platelets occurs in patients with extreme leukocytosis (>100,000/μL) or thrombocytosis (>1,000/μL); compare plasma potassium (which excludes cellular elements) to serum potassium to confirm. 3

---

True Refractory Hyperkalemia: Systematic Evaluation

If repeat venous sampling confirms persistent hyperkalemia despite standard therapy (calcium, insulin/glucose, albuterol, diuretics), proceed with the following diagnostic algorithm:

1. Assess Renal Potassium Excretion

Impaired renal excretion is the dominant cause of sustained hyperkalemia:

• Acute or chronic kidney disease with eGFR <15 mL/min/1.73 m² dramatically reduces potassium clearance; hyperkalemia becomes refractory when residual renal function is insufficient to eliminate daily potassium load. 1, 2, 4
• Oliguria or anuria (<400 mL urine/24 hours) indicates near-complete loss of renal potassium excretion; these patients require urgent hemodialysis for definitive potassium removal. 1
• Measure 24-hour urine potassium or spot urine potassium-to-creatinine ratio: values <15 mEq/day (or spot K/Cr <1.5) confirm impaired renal excretion as the primary mechanism. 5, 3

2. Identify Medication-Related Causes

Multiple potassium-retaining drugs create additive hyperkalemia risk:

• RAAS inhibitors (ACE inhibitors, ARBs, mineralocorticoid receptor antagonists) reduce aldosterone-mediated potassium secretion in the distal nephron; up to 50% of patients on these agents develop hyperkalemia in real-world settings. 2
• Potassium-sparing diuretics (amiloride, triamterene, spironolactone) directly block epithelial sodium channels in the collecting duct, impairing potassium excretion. 2, 6
• NSAIDs inhibit prostaglandin-mediated renal potassium excretion and reduce GFR, compounding hyperkalemia risk. 2
• Trimethoprim, heparin, beta-blockers, and calcineurin inhibitors all impair renal potassium handling through distinct mechanisms. 1, 2
• The triple combination of ACE inhibitor + ARB + MRA is NOT recommended due to excessive hyperkalemia risk. 1

3. Evaluate for Hypoaldosteronism

Reduced mineralocorticoid activity impairs distal tubular potassium secretion:

• Type IV renal tubular acidosis (hyporeninemic hypoaldosteronism) is common in diabetic nephropathy and presents with hyperkalemia, non-anion gap metabolic acidosis, and low urine potassium despite elevated serum levels. 5, 3
• Primary adrenal insufficiency causes combined aldosterone and cortisol deficiency; check morning cortisol and ACTH if suspected. 5
• Measure plasma renin and aldosterone levels in patients with unexplained hyperkalemia and metabolic acidosis; low renin and aldosterone confirm hyporeninemic hypoaldosteronism. 5, 3

4. Assess for Ongoing Potassium Release

Massive tissue breakdown releases intracellular potassium faster than kidneys can excrete it:

• Tumor lysis syndrome occurs within 12–72 hours after initiating chemotherapy in high-grade lymphomas or leukemias; rapid cell destruction releases massive potassium loads. 2, 7
• Rhabdomyolysis from trauma, prolonged immobilization, or statin toxicity causes myocyte lysis and potassium release; check creatine kinase (typically >5,000 U/L). 4, 5
• Massive hemolysis from transfusion reactions or hemolytic anemia releases erythrocyte potassium; check LDH, haptoglobin, and indirect bilirubin. 4
• These conditions require urgent hemodialysis because potassium release exceeds renal clearance capacity even with normal kidney function. 1

5. Exclude Transcellular Shift Without Total Body Excess

Potassium movement from intracellular to extracellular space can cause transient hyperkalemia:

• Metabolic acidosis (pH <7.35) drives potassium out of cells in exchange for hydrogen ions; each 0.1 unit decrease in pH raises serum potassium by ~0.6 mEq/L. 4, 5
• Insulin deficiency in uncontrolled diabetes or DKA impairs cellular potassium uptake; patients may have total body potassium depletion despite elevated serum levels. 4, 8
• Beta-blocker therapy reduces Na-K-ATPase activity, decreasing cellular potassium uptake. 1, 2
• Hyperglycemia causes hyperosmolality-driven water efflux from cells, dragging potassium into the extracellular space. 8, 5
• These patients are at high risk for rebound hypokalemia once the underlying cause (acidosis, hyperglycemia) is corrected; avoid aggressive potassium removal. 8

6. Consider Excessive Potassium Intake (Rare as Sole Cause)

Exogenous potassium load causes hyperkalemia only when renal excretion is impaired:

• High-potassium foods (bananas, melons, orange juice, potatoes, tomatoes, yogurt) contribute to hyperkalemia in patients with CKD but rarely cause it in isolation. 2
• Salt substitutes containing potassium chloride can deliver 10–15 mEq potassium per teaspoon; patients with renal impairment should avoid these entirely. 1, 2
• Stored blood products release potassium during storage; massive transfusion (>10 units) can cause hyperkalemia in critically ill patients. 2
• Breast milk has lower potassium than formula but excessive volumes can aggravate hyperkalemia in infants with renal impairment. 2

---

Why Standard Therapy Fails: Mechanisms of Refractoriness

Refractory hyperkalemia persists despite temporizing measures because:

• Calcium, insulin/glucose, and albuterol shift potassium intracellularly but do NOT remove it from the body; effects last only 2–6 hours before potassium redistributes back into serum. 1, 8
• Loop diuretics require adequate renal function (eGFR >30 mL/min) and euvolemia to enhance potassium excretion; they fail in oliguric AKI or ESRD. 1
• Sodium polystyrene sulfonate (Kayexalate) has limited efficacy and delayed onset (~4–6 hours), with serious GI risks including bowel necrosis; it should be avoided. 1, 7
• Ongoing potassium release (tumor lysis, rhabdomyolysis) exceeds clearance capacity even with maximal medical therapy; hemodialysis is required. 1, 4

---

Definitive Management Algorithm

Step 1: Confirm True Hyperkalemia

• Repeat venous sample with atraumatic technique to exclude pseudohyperkalemia. 1, 3

Step 2: Initiate Urgent Hemodialysis If:

• Serum potassium >6.5 mEq/L unresponsive to medical therapy 1
• Oliguria or anuria 1
• End-stage renal disease 1
• Ongoing potassium release (tumor lysis, rhabdomyolysis) 1, 4
• Persistent ECG changes despite calcium/insulin/albuterol 1

Step 3: Address Underlying Cause

• Hold RAAS inhibitors, NSAIDs, potassium-sparing diuretics, trimethoprim, heparin, beta-blockers 1, 2
• Correct metabolic acidosis with sodium bicarbonate ONLY if pH <7.35 and HCO₃ <22 mEq/L 1
• Treat insulin deficiency in DKA (but delay insulin until K⁺ >3.3 mEq/L to avoid rebound hypokalemia) 8
• Initiate rasburicase or allopurinol for tumor lysis syndrome 2

Step 4: Prevent Recurrence

• Initiate sodium zirconium cyclosilicate (SZC/Lokelma) 10 g TID × 48 hours, then 5–15 g daily for rapid potassium binding (onset ~1 hour). 1, 7
• Patiromer (Veltassa) 8.4 g daily with food for chronic management (onset ~7 hours); separate from other meds by ≥3 hours. 1, 7
• Restart RAAS inhibitors at lower dose once K⁺ <5.0 mEq/L with concurrent potassium binder to maintain cardioprotective therapy. 1

---

Critical Pitfalls to Avoid

• Do not assume ABG potassium is accurate without verifying with venous sample; hemolysis during arterial puncture is extremely common. 1, 3
• Do not rely on temporizing measures (calcium, insulin, albuterol) in patients with impaired renal function; these do not remove potassium and effects are transient. 1, 8
• Do not use sodium polystyrene sulfonate (Kayexalate); it has limited efficacy and serious GI risks including bowel necrosis. 1, 7
• Do not permanently discontinue RAAS inhibitors; use potassium binders to enable continuation of these life-saving medications. 1
• Do not delay hemodialysis in oliguric patients or those with ongoing potassium release; medical therapy alone will fail. 1, 4